Prostatype Genomics AB (the “Company”) has entered into short-term loan agreements of SEK 6.5 million with major shareholders and SEK 3.5 million with external lenders, with the option of further SEK 2.0 million.
The loans carry a fixed interest rate of about 15 percent and shall be repaid, including accrued interest, no later than 30 June 2026.
– The loans strengthen our short-term financial flexibility and allow us to maintain focus on the Company’s strategic and operative priorities without immediate dilution for shareholders, says Fredrik Rickman, CEO of Prostatype Genomics AB.
The external lenders consist of a consortium, Finance Lab AB (https://financelab.se).
For more information, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
Email: fredrik.rickman@prostatypegenomics.com
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.